A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Study Summary

This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.

Conditions

Dravet Syndrome

Interventions / Drugs

LP352 Placebo

View on ClinicalTrials.gov ↗

Sponsor

LBPH

Longboard Pharmaceuticals

Oncology

B66/100

Study Details

Enrollment160 participants

Primary Completion—

Lead SponsorLongboard Pharmaceuticals

Data Retrieved2026-04-11 04:19:23.274023+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.